<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02288182</url>
  </required_header>
  <id_info>
    <org_study_id>CR03/13</org_study_id>
    <nct_id>NCT02288182</nct_id>
  </id_info>
  <brief_title>Randomized, Controlled Study to Compare Straumann® VivOss™ to Geistlich Bio-Oss® in Sinus Floor Augmentation.</brief_title>
  <official_title>A Randomized Controlled Clinical Trial to Investigate the Capability of Straumann® VivOss™ Compared to Geistlich Bio-Oss® in Sinus Floor Augmentation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Straumann AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Straumann AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized controlled clinical trial to investigate the capability of Straumann® VivOss™
      compared to Geistlich Bio-Oss in sinus floor augmentation to demonstrate superiority of
      Straumann® VivOss™ compared to Geistlich Bio-Oss in regards to the ratio of newly formed bone
      to residual bone substitute.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, controlled study. The total study duration for each
      patient should be 9-14 months (from screening to last visit).

      Enrolled subjects are randomized to one of the following groups:

        1. Sinus floor elevation with Straumann® VivOss™

        2. Sinus floor elevation with Geistlich Bio-Oss®

      In total 6 visits per patient are scheduled in this study. The histological evaluation of the
      ratio of newly formed bone to residual bone graft, survival and success rate of study
      implants and adverse events (AEs) will be assessed.

      The study devices Straumann® VivOss™ and Geistlich Bio-Oss are CE-(Conformité Européenne,
      meaning European Conformity) marked products.

      Two centers, one in Germany and one in Switzerland will participate.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2014</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ratio of Newly Formed Bone to Residual Bone Graft in Patients Treated With Straumann® VivOss™ Compared to Geistlich Bio-Oss®</measure>
    <time_frame>6 months +/- 7 days after bone augmentation</time_frame>
    <description>Bone biopsies and histological staining</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival Rate of Study Implants (Based on Subjects)</measure>
    <time_frame>4 months +/- 1 month after implant placement</time_frame>
    <description>Number of implants in place</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success Rate of Study Implants</measure>
    <time_frame>4 months +/- 1 month after implant placement</time_frame>
    <description>Buser success criteria:
Absence of persisting subjective discomfort such as pain, foreign body perception and or dysaesthesia (painful sensation)
Absence of a recurrent peri-implant infection with suppuration (where an infection is termed recurrent if it is observed at two or more follow-up visits after treatment with systemic antibiotics)
Absence of implant mobility on manual palpation
Absence of any continuous peri-implant radiolucency.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Basic Bone Situation</measure>
    <time_frame>6 months +/- 7 days after bone augmentation</time_frame>
    <description>This measure describes the basic bone situation of the patients at baseline, i.e. the bone thickness as a unit of area before the application of bone substitute material.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Straumann VivOss</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Straumann® VivOss™Straumann® VivOss™, is a synthetic bone graft substitute in granulated form. It consists of &gt; 90% TCP (Tri-Calcium-Phosphate -Ca3(PO4)2) and &lt; 10% Hydroxyapatite (Ca10(PO4)6 (OH)2). The granules have a size of 250-1000 μm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Geistlich Bio-Oss</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control device is Geistlich Bio-Oss® spongiosa granules (Geistlich Pharma AG, Wolhusen, Switzerland), 0.25-1 mm in diameter. It's a natural bone mineral of bovine origin. It shall be used according to the instructions of the manufacturer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Straumann VivOss</intervention_name>
    <description>Patients will receive Straumann VivOss for sinus augmentation.</description>
    <arm_group_label>Straumann VivOss</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Geistlich Bio-Oss</intervention_name>
    <description>Patients will receive Geistlich Bio-Oss for sinus augmentation.</description>
    <arm_group_label>Geistlich Bio-Oss</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must have voluntarily signed the informed consent before any study related
             action

          -  Males and females with at least 18 years of age (including 18 years)

          -  Subject needs augmentation procedure in the sinus to prepare for implant placement.

          -  Subject must have a residual bone height of 2 to 4 mm.

          -  Adequate oral hygiene ((Full mouth plaque index (O'Leary, et al. 1972 ) &lt;25%) at
             baseline

          -  Adequate control of inflammation ((full mouth bleeding on probing (Ainamo and Bay
             1975)) ≤25% at baseline

        Exclusion Criteria:

          -  Systemic disease that would interfere with bone or wound healing and dental implant
             therapy (e.g. uncontrolled diabetes)

          -  Systemic disease that would interfere with bone or wound healing and dental implant
             therapy (e.g. uncontrolled diabetes)

          -  Any contraindications for general bone grafting and oral surgical procedures

          -  Any anomalies of the sinus that could interfere with planned procedures

          -  History of local irradiation therapy

          -  Local inflammation, including untreated periodontitis

          -  Medical conditions requiring chronic high dose steroid therapy

          -  Treatment with an investigational drug or device within a 30 day period immediately
             prior to surgery at visit 2, or expected participation in any other investigational
             drug or device study during the conduct of this trial.

          -  Antibiotic treatment or anti-inflammatory treatment within 4 weeks prior to surgery

          -  History of alcoholism or drug abuse

          -  Immunocompromised subjects

          -  Subjects who smoke &gt;10 cigarettes per day or tobacco equivalents or chew tobacco

          -  Conditions or circumstances, in the opinion of the investigator, which would prevent
             completion of study participation or interfere with analysis of study results, such as
             history of non-compliance or unreliability

          -  Physical or mental disabilities that would interfere with the ability to perform
             adequate oral hygiene

          -  Current pregnancy (pregnancy test) and breastfeeding women

        Secondary exclusion criterium:

        Defects of the Schneider Membrane
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Jung, PD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zentrum für Implantologie, Parodontologie und 3D- Diagnostik</name>
      <address>
        <city>Konstanz</city>
        <state>Baden-Württemberg</state>
        <zip>78462</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Buser D, Weber HP, Lang NP. Tissue integration of non-submerged implants. 1-year results of a prospective study with 100 ITI hollow-cylinder and hollow-screw implants. Clin Oral Implants Res. 1990 Dec;1(1):33-40.</citation>
    <PMID>2099210</PMID>
  </results_reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>October 28, 2014</study_first_submitted>
  <study_first_submitted_qc>November 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2014</study_first_posted>
  <results_first_submitted>July 24, 2018</results_first_submitted>
  <results_first_submitted_qc>August 26, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 28, 2019</results_first_posted>
  <last_update_submitted>August 26, 2019</last_update_submitted>
  <last_update_submitted_qc>August 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sinus augmentation procedure</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 19, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT02288182/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Straumann VivOss</title>
          <description>Subjects were randomized either to the test group receiving Straumann VivOss oder comparator group receiving Geistlich Bio-Oss. If a patient needed augmentation in both sinuses, one sinus was randomized into the test group receiving Straumann VivOss and the other (opposite) sinus should be treated with Geistlich Bio-Oss. In those bilateral patients, biopsies were taken from both sinuses.</description>
        </group>
        <group group_id="P2">
          <title>Geistlich Bio-Oss</title>
          <description>Subjects were randomized either to the test group receiving Straumann VivOss oder comparator group receiving Geistlich Bio-Oss. If a patient needed augmentation in both sinuses, one sinus was randomized into the test group receiving Straumann VivOss and the other (opposite) sinus should be treated with Geistlich Bio-Oss. In those bilateral patients, biopsies were taken from both sinuses.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ITT Data Set</population>
      <group_list>
        <group group_id="B1">
          <title>Straumann VivOss</title>
          <description>Subjects were randomized either to the test group receiving Straumann VivOss oder comparator group receiving Geistlich Bio-Oss. If a patient needed augmentation in both sinuses, one sinus was randomized into the test group receiving Straumann VivOss and the other (opposite) sinus should be treated with Geistlich Bio-Oss. In those bilateral patients, biopsies were taken from both sinuses.</description>
        </group>
        <group group_id="B2">
          <title>Geistlich Bio-Oss</title>
          <description>Subjects were randomized either to the test group receiving Straumann VivOss oder comparator group receiving Geistlich Bio-Oss. If a patient needed augmentation in both sinuses, one sinus was randomized into the test group receiving Straumann VivOss and the other (opposite) sinus should be treated with Geistlich Bio-Oss. In those bilateral patients, biopsies were taken from both sinuses.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.4" spread="11.8"/>
                    <measurement group_id="B2" value="60.3" spread="9.9"/>
                    <measurement group_id="B3" value="59.3" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ratio of Newly Formed Bone to Residual Bone Graft in Patients Treated With Straumann® VivOss™ Compared to Geistlich Bio-Oss®</title>
        <description>Bone biopsies and histological staining</description>
        <time_frame>6 months +/- 7 days after bone augmentation</time_frame>
        <population>The biopsies were retrieved from the central part of the dental implant osteotomy. In patients with bilateral treatment, biopsies were taken from both sinuses.</population>
        <group_list>
          <group group_id="O1">
            <title>Straumann VivOss</title>
            <description>Straumann® VivOss™, is a synthetic bone graft substitute in granulated form. It consists of &gt; 90% TCP (Tri-Calcium-Phosphate –Ca3(PO4)2) and &lt; 10% Hydroxyapatite (Ca10(PO4)6 (OH)2). The granules have a size of 250-1000 μm.
Straumann VivOss: Patients will receive Straumann VivOss for sinus augmentation.</description>
          </group>
          <group group_id="O2">
            <title>Geistlich Bio-Oss</title>
            <description>The control device is Geistlich Bio-Oss® spongiosa granules (Geistlich Pharma AG, Wolhusen, Switzerland), 0.25-1 mm in diameter. It’s a natural bone mineral of bovine origin. It shall be used according to the instructions of the manufacturer.
Geistlich Bio-Oss: Patients will receive Geistlich Bio-Oss for sinus augmentation.</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Newly Formed Bone to Residual Bone Graft in Patients Treated With Straumann® VivOss™ Compared to Geistlich Bio-Oss®</title>
          <description>Bone biopsies and histological staining</description>
          <population>The biopsies were retrieved from the central part of the dental implant osteotomy. In patients with bilateral treatment, biopsies were taken from both sinuses.</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <units_analyzed>biopsies</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>biopsies</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" lower_limit="1.00" upper_limit="2.22"/>
                    <measurement group_id="O2" value="0.69" lower_limit="0.58" upper_limit="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Student's t-test comparing the group means was planned and performed (successfully). However, due to some outliers, the central tendencies have been reported as medians (instead of arithmetic means). Therefore an additional non-parameteric test (Mann-Whitney U-test) was performed.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival Rate of Study Implants (Based on Subjects)</title>
        <description>Number of implants in place</description>
        <time_frame>4 months +/- 1 month after implant placement</time_frame>
        <population>ITT Data Set</population>
        <group_list>
          <group group_id="O1">
            <title>Straumann VivOss</title>
            <description>Subjects were randomized either to the test group receiving Straumann VivOss oder comparator group receiving Geistlich Bio-Oss. If a patient needed augmentation in both sinuses, one sinus was randomized into the test group receiving Straumann VivOss and the other (opposite) sinus should be treated with Geistlich Bio-Oss. In those bilateral patients, biopsies were taken from both sinuses.</description>
          </group>
          <group group_id="O2">
            <title>Geistlich Bio-Oss</title>
            <description>Subjects were randomized either to the test group receiving Straumann VivOss oder comparator group receiving Geistlich Bio-Oss. If a patient needed augmentation in both sinuses, one sinus was randomized into the test group receiving Straumann VivOss and the other (opposite) sinus should be treated with Geistlich Bio-Oss. In those bilateral patients, biopsies were taken from both sinuses.</description>
          </group>
        </group_list>
        <measure>
          <title>Survival Rate of Study Implants (Based on Subjects)</title>
          <description>Number of implants in place</description>
          <population>ITT Data Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Success Rate of Study Implants</title>
        <description>Buser success criteria:
Absence of persisting subjective discomfort such as pain, foreign body perception and or dysaesthesia (painful sensation)
Absence of a recurrent peri-implant infection with suppuration (where an infection is termed recurrent if it is observed at two or more follow-up visits after treatment with systemic antibiotics)
Absence of implant mobility on manual palpation
Absence of any continuous peri-implant radiolucency.</description>
        <time_frame>4 months +/- 1 month after implant placement</time_frame>
        <population>ITT Data Set</population>
        <group_list>
          <group group_id="O1">
            <title>Straumann VivOss</title>
            <description>Subjects were randomized either to the test group receiving Straumann VivOss oder comparator group receiving Geistlich Bio-Oss. If a patient needed augmentation in both sinuses, one sinus was randomized into the test group receiving Straumann VivOss and the other (opposite) sinus should be treated with Geistlich Bio-Oss. In those bilateral patients, biopsies were taken from both sinuses.</description>
          </group>
          <group group_id="O2">
            <title>Geistlich Bio-Oss</title>
            <description>Subjects were randomized either to the test group receiving Straumann VivOss oder comparator group receiving Geistlich Bio-Oss. If a patient needed augmentation in both sinuses, one sinus was randomized into the test group receiving Straumann VivOss and the other (opposite) sinus should be treated with Geistlich Bio-Oss. In those bilateral patients, biopsies were taken from both sinuses.</description>
          </group>
        </group_list>
        <measure>
          <title>Success Rate of Study Implants</title>
          <description>Buser success criteria:
Absence of persisting subjective discomfort such as pain, foreign body perception and or dysaesthesia (painful sensation)
Absence of a recurrent peri-implant infection with suppuration (where an infection is termed recurrent if it is observed at two or more follow-up visits after treatment with systemic antibiotics)
Absence of implant mobility on manual palpation
Absence of any continuous peri-implant radiolucency.</description>
          <population>ITT Data Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Basic Bone Situation</title>
        <description>This measure describes the basic bone situation of the patients at baseline, i.e. the bone thickness as a unit of area before the application of bone substitute material.</description>
        <time_frame>6 months +/- 7 days after bone augmentation</time_frame>
        <population>ITT Data Set</population>
        <group_list>
          <group group_id="O1">
            <title>Straumann VivOss</title>
            <description>Subjects were randomized either to the test group receiving Straumann VivOss oder comparator group receiving Geistlich Bio-Oss. If a patient needed augmentation in both sinuses, one sinus was randomized into the test group receiving Straumann VivOss and the other (opposite) sinus should be treated with Geistlich Bio-Oss. In those bilateral patients, biopsies were taken from both sinuses.</description>
          </group>
          <group group_id="O2">
            <title>Geistlich Bio-Oss</title>
            <description>Subjects were randomized either to the test group receiving Straumann VivOss oder comparator group receiving Geistlich Bio-Oss. If a patient needed augmentation in both sinuses, one sinus was randomized into the test group receiving Straumann VivOss and the other (opposite) sinus should be treated with Geistlich Bio-Oss. In those bilateral patients, biopsies were taken from both sinuses.</description>
          </group>
        </group_list>
        <measure>
          <title>Basic Bone Situation</title>
          <description>This measure describes the basic bone situation of the patients at baseline, i.e. the bone thickness as a unit of area before the application of bone substitute material.</description>
          <population>ITT Data Set</population>
          <units>mm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="0.42"/>
                    <measurement group_id="O2" value="1.27" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Overall study period (10 months per patient)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Straumann VivOss</title>
          <description>Subjects were randomized either to the test group receiving Straumann VivOss oder comparator group receiving Geistlich Bio-Oss. If a patient needed augmentation in both sinuses, one sinus was randomized into the test group receiving Straumann VivOss and the other (opposite) sinus should be treated with Geistlich Bio-Oss. In those bilateral patients, biopsies were taken from both sinuses.</description>
        </group>
        <group group_id="E2">
          <title>Geistlich Bio-Oss</title>
          <description>Subjects were randomized either to the test group receiving Straumann VivOss oder comparator group receiving Geistlich Bio-Oss. If a patient needed augmentation in both sinuses, one sinus was randomized into the test group receiving Straumann VivOss and the other (opposite) sinus should be treated with Geistlich Bio-Oss. In those bilateral patients, biopsies were taken from both sinuses.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>urinary tract infection (leading to hospitalization)</sub_title>
                <description>This was an unexpected event withount any causal relationship to study procedures or devices.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>swelling</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>compromised wound healing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>dehiscence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>implant loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>explantation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Manfred Klasser</name_or_title>
      <organization>gwd consult · contract research</organization>
      <phone>+49 (6108) 8256520</phone>
      <email>manfred.klasser@gwd-consult.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

